STAT+: Counter-culture or pharma: Group behind MDMA therapy for PTSD wrestles with its identity
DENVER — He could have been a rock star, a religious icon, the way ecstatic…
Category: Pharma
STAT+: Pharmalittle: FDA declines to approve higher dose version of Regeneron eye drug; FDA warns wholesaler over counterfeit HIV pills
Good morning, everyone, and how are you today? We are doing just fine, thank you….
STAT+: ‘It’s like Groundhog Day’: The cancer drug shortage isn’t new — and neither are the solutions
A young girl, maybe 5 or 6 years old, had come into Yoram Unguru’s clinic…
STAT+: FDA issues warning to wholesaler sued by Gilead and J&J for distributing counterfeit medicines
A year after two major drugmakers sued a wholesaler for its alleged role in distributing…
STAT+: After late start, Eli Lilly starts pulling ahead in race for the $30 billion weight loss market
SAN DIEGO — It was Novo Nordisk’s Ozempic and Wegovy that set off a new…
STAT+: Lilly reaches $2.4 million settlement with EEOC over age discrimination lawsuit
Eli Lilly agreed to pay $2.4 million as part of a settlement with the U.S….
STAT+: Pharmalittle: Lilly drug shows biggest weight loss yet in mid-stage trial; Biogen shareholders elect director’s romantic partner to the board
Top of the morning to you. The middle of the week is upon us and,…
STAT+: Pharmalittle: Nearly half of U.S. adults would spend $100 a month for weight loss drugs; Pfizer scraps an obesity pill
Good morning, everyone. and welcome to another working week. We hope the weekend respite was…
STAT+: STAT-Harris Poll: Nearly half of U.S. adults would spend $100 a month for Ozempic, other weight-loss drugs
Almost half of Americans would be willing to spend up to $100 a month for…
STAT+: Lilly’s obesity pill cuts 15% of weight at highest dose in mid-stage trial
SAN DIEGO – An experimental pill from Eli Lilly led to 14.7% weight loss on…
STAT+: Pharmalittle: FDA approves first gene therapy for Duchenne muscular dystrophy; states join FTC to stop Amgen deal
And so, another working week will soon draw to a close. Not a moment too…
STAT+: GSK settles first lawsuit set for a U.S. trial over cancer links to Zantac
GSK reached a settlement with a man who claimed its Zantac heartburn medication caused his…
STAT+: Using its Covid know-how, Color Health aims to make cancer screenings convenient
Color Health wants to take away any reason you might have for skipping screenings for…
STAT+: The strategy behind the pharmaceutical industry’s flurry of lawsuits challenging drug pricing reform
WASHINGTON — The pharmaceutical industry has been filing a lawsuit here, there, and pretty much everywhere….
STAT+: Pharmalittle: Europe regulator raised safety signal on Novo drugs; U.S. seeks new trial over royalties on Gilead HIV prevention pills
Top of the morning to you. Gray skies are hovering over the Pharmalot campus right…
STAT+: U.S. seeks a new trial over royalties on Gilead HIV prevention pills
The U.S. government asked a federal judge to overturn a recent case in which a…
STAT+: Drug middlemen catch flak at another congressional hearing
Drug middlemen once again were on the hot seat at a congressional hearing on Wednesday….
Sen. Grassley calls on GOP leaders to rally support for PBM reforms
WASHINGTON — Republican Sen. Chuck Grassley wants to see his party’s leadership turn up the…
STAT Virtual Event: The Next Frontier of Drug Pricing Reform
Editor’s note: A livestream of the event will be embedded below at 1 p.m. ET….
STAT+: Pharmalittle: Novo Nordisk sues spas, clinics over compounded Wegovy; top lobbyist leaves PhRMA
Hello, everyone, and how are you this fine, sunny morning? The middle of the week…
STAT+: Novo Nordisk sues spas and clinics for selling versions of Wegovy and Ozempic for weight loss
In the latest fracas over obesity drugs, Novo Nordisk filed lawsuits alleging several medical spas,…
STAT+: Pharmalittle: Opaque conflicts permeate prescription drug benefits; Sanofi prevails in Zantac arbitration
Rise and shine, everyone, another busy day is on the way. We can tell by…
STAT+: ‘It’s beyond unethical’: Opaque conflicts of interest permeate prescription drug benefits
Employers across the country — from big names like Boeing and UPS to local school…
STAT+: How drug pricing reforms are affecting Bayer’s investments
WASHINGTON — Pharma companies have long been warning Democrats’ drug pricing reforms could discourage investment in…
STAT+: Pharmalittle: Bristol Myers sues HHS over Medicare drug negotiations; Lilly reports new shortages of Mounjaro diabetes drug
Good morning, everyone, and welcome to another working week, albeit an abbreviated one for many,…
Opinion: Cancer drug shortages should have patients rioting in the streets
Cancer patients, like those I treat in San Diego and thousands more across the country,…
STAT+: Trade group scolds drugmaker for ‘unethical’ attempt to gain info about rival product
In a notable move, a U.K. trade group has rebuked Leo Pharma for a “serious…
STAT+: Pharmalittle: FDA cites another troubled plant at company contributing to cancer drug shortages; USDA to push food producers over antibiotic claims
And so, another working week will soon draw to a close. Not a moment too…
.jpg)
Opinion: The FDA needs a risk evaluation and mitigation strategy for Alzheimer’s drug lecanemab
Over the past several months, my conversations with colleagues in the Alzheimer’s field have featured…
STAT+: USDA to push food producers to substantiate claims that animals are raised without antibiotics
The U.S. Department of Agriculture is launching a program to ensure food producers substantiate claims…
STAT+: Pharmalittle: PBMs are targeted in yet another congressional bill; access to new Alzheimer’s drug may not happen quickly
Rise and shine, another busy day is on the way. However, this is also shaping…
Opinion: STAT+: How I’m helping companies think through whether they should cover GLP-1s like Ozempic for employees
We have a knack in the U.S. for blurring behavior and medicine. Look at weight….
STAT+: Pharmalittle: A not-so-new Biogen?; ALS Association and 15 chapters part ways over organizational clashes
Rise and shine, everyone. The middle of the week is upon us. Have heart, though….
STAT+: Bitter infighting leads 15 chapters to break away from leading ALS advocacy group
After a bitter dispute, the ALS Association has settled a lawsuit filed by 15 chapters…
STAT+: Key House Republican escalates rhetoric against PBMs
WASHINGTON — A key House Republican ramped up his criticism of pharmacy benefit managers Tuesday,…
STAT+: Sanders wants NIH to adopt ‘reasonable pricing’ language for drugs that agency research helps develop
In another bid to lower prescription drug prices, U.S. Sen. Bernie Sanders (I-Vt.) issued a…
STAT+: Pharmalittle: Exec nominated to Biogen board is mother of outgoing director’s child; telehealth company pauses Wegovy ads amid shortages
Top of the morning to you, and a fine one it is. Sunny skies and…
STAT+: Pharmalittle: U.S. Chamber sues over Medicare price negotiations; FDA seeks new supplier for scarce cancer drug
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: Chamber of Commerce tries new legal arguments to challenge Medicare drug-price negotiation
WASHINGTON — The U.S. Chamber of Commerce sued the federal government over its new Medicare drug-price…
STAT+: Drug companies and pharmacies reach $17.3 billion settlement over opioid crisis
Two large drugmakers and two of the biggest pharmacy chains finalized a $17.3 billion deal…
STAT+: Pharmalittle: FDA panel to review Alzheimer’s treatment; FDA advisers back approval of RSV drug for children
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Tracking the FDA advisory panel on Eisai and Biogen’s treatment for Alzheimer’s disease
The Food and Drug Administration is convening a meeting of outside experts on Friday to…
STAT+: If AI invents a new medicine, who gets the patent?
Pharmaceutical and biotech companies are increasingly using artificial intelligence to discover and make drugs and…
STAT+: Pharmalittle: FDA commish calls U.S. drug prices ‘too high’; FDA staff says Eisai and Biogen’s Alzheimer’s drug has benefits
Rise and shine, everyone, another busy day is on the way, although the smoky covering…
STAT+: Sen. Cassidy wants to put a stop to FDA delays in drug review process
WASHINGTON – Sen. Bill Cassidy (R-La.) is looking into ways to speed up the Food…
STAT+: ‘We don’t agree’ on drug pricing policy, FDA chief tells biotech leaders
BOSTON — The drug industry has spent the past year speaking against new mechanisms that…
STAT+: After missing vaccine glory in pandemic, GSK looks to dominate other diseases
BOSTON — GSK has been developing vaccines under one corporate guise or another for 140…
STAT+: Pharmalittle: U.K. launches pilot to expand access to weight loss drugs; European Union approves RSV vaccine
Top of the morning to you, and a fine one it is. Well, sort of….
STAT+: ASCO showcased the payoff for new cancer medicines: longer lives
CHICAGO — Well, that’s a wrap. The biggest meeting in cancer research — and, really,…
STAT+: FDA will allow troubled chemotherapy maker to resume distribution of cancer drugs in short supply
After finding a “cascade of failures” at a manufacturing plant run by a key chemotherapy…